ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

TargetBeta

CEACAM5

CEA cell adhesion molecule 5 · also CD66e, CEA · CD molecules

6 programs in company-led studies act on CEACAM5, from 6 companies: 1 in phase 3. Each with where its target was read from.

Programs

Furthest phase first. A target read by rule is marked rule (4 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.

ProgramCompanyActs asFurthest phaseStudiesAlso acts onRead from
precemtabart tocentecanruleMerck KGaA, Darmstadt, Germany–phase 343 running–NCIt
Anti-CEA/Anti-4-1BB Bispecific Antibody LM-24C5Sino Biopharmaceutical–phase 222 runningTNFRSF9the company's pipeline
Anti-CEACAM5 Antibody-drug Conjugate BMS-986490ruleBristol-Myers Squibb–phase 211 running–NCIt
Anti-CEACAM5 Antibody-drug Conjugate IBI3020ruleInnovent Biologics–phase 111 running–NCIt
RO7821657ruleHoffmann-La Roche–phase 111 running–the studies' text
tusamitamab sonditecanPfizer–phase 111 running–the company's pipeline

Also acted on by the same programs

Conditions their studies are in

Primary completions ahead

Each program’s next study to reach its primary completion, by the sponsor’s estimate.

What this can’t show

  • Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
  • A target read by rule can be wrong; each program’s page quotes the words it was read from.
  • “Acts as” is read from the words its target was read from — agonist, antagonist, inhibitor, lowers it (an siRNA or antisense drug), degrader — and is a dash where they do not say, or say two things; an antibody that only “binds” says neither.
  • Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.